Aankondiging • Aug 16
PhaseBio Pharmaceuticals, Inc. announced delayed 10-Q filing On 08/15/2024, PhaseBio Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Aankondiging • May 18
PhaseBio Pharmaceuticals, Inc. announced delayed 10-Q filing On 05/16/2024, PhaseBio Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Aankondiging • May 15
Amended Disclosure Statement Conditionally Approved for PhaseBio Pharmaceuticals, Inc. The US Bankruptcy Court conditionally approved the modified first amended plan and disclosure statement of PhaseBio Pharmaceuticals, Inc. on May 13, 2024. The debtor had filed its amended disclosure statement in the Court on May 13, 2024. May 13, 2024 has been fixed as voting record date. The deadline to vote on the plan and the plan objection deadline is June 17, 2024. The confirmation hearing for the plan has been scheduled for June 26, 2024. Aankondiging • Apr 03
PhaseBio Pharmaceuticals, Inc. announced delayed annual 10-K filing On 04/02/2024, PhaseBio Pharmaceuticals, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Aankondiging • Nov 17
PhaseBio Pharmaceuticals, Inc. announced delayed 10-Q filing On 11/15/2023, PhaseBio Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Aankondiging • Aug 26
PhaseBio Pharmaceuticals, Inc. announced delayed 10-Q filing On 08/25/2023, PhaseBio Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Aankondiging • May 17
PhaseBio Pharmaceuticals, Inc. announced delayed 10-Q filing On 05/16/2023, PhaseBio Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Aankondiging • Jan 18
Chiesi Farmaceutici S.p.A. completed the acquisition of all of the assets of PhaseBio Pharmaceuticals, Inc. primarily related to bentracimab. Chiesi Farmaceutici S.p.A. entered into an agreement to acquire all of the assets of PhaseBio Pharmaceuticals, Inc. primarily related to bentracimab for $100 million on November 4, 2022. As per the terms of the transaction, $40 million in cash to be paid at the closing of the Transaction (subject to adjustment), plus future contingent payments of up to $60 million (the “Milestone Payments”) in cash upon the completion of certain regulatory milestone events. Chiesi is required to deposit $4 million (the “Deposit Funds”) with an escrow agent within three business days after the execution of the Agreement, which amount will be credited against the purchase price payable by Chiesi upon the closing of the Transaction. PhaseBio will be required to pay Chiesi a break-up fee of $2 million. The Transaction, and the designation of Chiesi as the stalking horse bidder, is subject to the approval of the Bankruptcy Court. The completion of the Transaction is subject to a number of customary conditions, including that a specified number of required employees shall have accepted and not rescinded offers of employment or engagement as a consultant or independent contractor with Chiesi and any waiting period applicable to the transaction under any Antitrust Law shall have expired or been terminated. As of January 5, 2023, the transaction has received the approval from the bankruptcy court. Christian E. Plaza of Cooley LLP acted as legal advisor to PhaseBio. Heyward D. Armstrong and Justin G. Truesdale of Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, L.L.P. and A. Lee Hogewood III and John R. Gardner of K&L Gates LLP both acted as legal advisors to Chiesi.
Chiesi Farmaceutici S.p.A. completed the acquisition of all of the assets of PhaseBio Pharmaceuticals, Inc. primarily related to bentracimab on January 17, 2023. Price Target Changed • Sep 28
Price target increased to US$18.00 Up from US$14.33, the current price target is an average from 5 analysts. New target price is 6,904% above last closing price of US$0.26. Stock is down 92% over the past year. The company is forecast to post a net loss per share of US$1.22 next year compared to a net loss per share of US$2.98 last year. Major Estimate Revision • Aug 19
Consensus revenue estimates fall by 68% The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from US$9.47m to US$3.06m. Forecast losses increased from -US$1.07 to -US$1.22 per share. Biotechs industry in the US expected to see average net income decline 57% next year. Consensus price target of US$13.67 unchanged from last update. Share price fell 5.0% to US$1.13 over the past week. Major Estimate Revision • May 23
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$14.7m to US$9.47m. EPS estimate increased from -US$2.03 to -US$1.07 per share. Biotechs industry in the US expected to see average net income decline 52% next year. Consensus price target of US$14.33 unchanged from last update. Share price fell 13% to US$0.81 over the past week. Price Target Changed • Apr 27
Price target decreased to US$14.33 Down from US$16.00, the current price target is an average from 5 analysts. New target price is 1,191% above last closing price of US$1.11. Stock is down 64% over the past year. The company is forecast to post a net loss per share of US$2.03 next year compared to a net loss per share of US$2.98 last year. Price Target Changed • Dec 16
Price target increased to US$16.00 Up from US$14.00, the current price target is an average from 5 analysts. New target price is 599% above last closing price of US$2.29. Stock is down 47% over the past year. The company is forecast to post a net loss per share of US$2.65 next year compared to a net loss per share of US$3.39 last year. Recent Insider Transactions Derivative • Nov 11
Independent Director exercised options to buy US$116k worth of stock. On the 8th of November, Nancy Hutson exercised options to buy 34k shares at a strike price of around US$2.49, costing a total of US$84k. This transaction amounted to 844% of their direct individual holding at the time of the trade. Since March 2021, Nancy's direct individual holding has increased from 1.00k shares to 4.00k. Company insiders have collectively bought US$224k more than they sold, via options and on-market transactions, in the last 12 months. Executive Departure • Sep 16
Independent Director Peter Klein has left the company On the 14th of September, Peter Klein's tenure as Independent Director ended after 11.8 years in the role. As of June 2021, Peter still personally held only 2.30k shares (US$8.6k worth at the time). Peter is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 4.33 years. Major Estimate Revision • Aug 19
Consensus forecasts updated The consensus outlook for 2021 has been updated. 2021 revenue forecast increased from US$5.08m to US$10.8m. EPS estimate fell from -US$2.31 to -US$2.56 per share. Biotechs industry in the US expected to see average net income decline 21% next year. Consensus price target of US$14.33 unchanged from last update. Share price fell 9.3% to US$3.03 over the past week. Major Estimate Revision • Jun 19
Consensus revenue estimates increase to US$4.07m The consensus outlook for revenues in 2021 has improved. 2021 revenue forecast increased from US$67.2k to US$4.07m. Forecast losses expected to reduce from -US$2.41 to -US$2.31 per share. Biotechs industry in the US expected to see average net income decline 5.1% next year. Consensus price target down from US$14.00 to US$12.75. Share price was steady at US$3.75 over the past week. Price Target Changed • Jun 19
Price target decreased to US$12.75 Down from US$14.00, the current price target is an average from 5 analysts. New target price is 240% above last closing price of US$3.75. Stock is down 26% over the past year. Major Estimate Revision • May 20
Consensus EPS estimates increase to -US$2.31 The consensus outlook for earnings per share (EPS) in 2021 has improved. 2021 revenue forecast increased from US$76.8k to US$84.0k. EPS estimate increased from -US$2.74 to -US$2.31. Biotechs industry in the US expected to see average net income decline 6.3% next year. Consensus price target of US$14.00 unchanged from last update. Share price rose 14% to US$3.19 over the past week. Major Estimate Revision • Mar 23
Consensus revenue estimates fall to US$76.8k The consensus outlook for revenues in 2021 has deteriorated. 2021 revenue forecast decreased from US$353.2k to US$76.8k. Forecast losses increased from -US$2.44 to -US$2.74 per share. Biotechs industry in the US expected to see average net income growth of 4.2% next year. Consensus price target up from US$13.50 to US$15.00. Share price fell 3.2% to US$3.88 over the past week. Price Target Changed • Mar 19
Price target increased to US$15.00 Up from US$13.50, the current price target is an average from 5 analysts. New target price is 287% above last closing price of US$3.88. Stock is up 34% over the past year. Reported Earnings • Mar 17
Full year 2020 earnings released: US$3.39 loss per share (vs US$1.43 loss in FY 2019) Full year 2020 results: Net loss: US$98.6m (loss widened 151% from FY 2019). Products in clinical trials Phase II: 1 Phase III: 1 Is New 90 Day High Low • Feb 09
New 90-day high: US$4.45 The company is up 30% from its price of US$3.41 on 10 November 2020. The American market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 25% over the same period. Price Target Changed • Jan 07
Price target lowered to US$13.50 Down from US$14.75, the current price target is an average from 5 analysts. The new target price is 263% above the current share price of US$3.72. As of last close, the stock is down 32% over the past year. Is New 90 Day High Low • Dec 16
New 90-day high: US$4.44 The company is up 27% from its price of US$3.49 on 16 September 2020. The American market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 17% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Is New 90 Day High Low • Dec 01
New 90-day high: US$3.80 The company is up 2.0% from its price of US$3.72 on 01 September 2020. The American market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Major Estimate Revision • Nov 26
Analysts lower revenue estimates to US$296.0k The 2020 consensus revenue estimate decreased from US$375.0k. Earnings per share (EPS) also decreased, with analysts lowering their estimates from -US$2.95 to -US$3.02 for the same period. The Biotechs industry in the US is expected to see an average net income growth of 7.0% next year. The consensus price target of US$14.25 was unchanged from the last update. Share price is up 3.4% to US$3.69 over the past week. Major Estimate Revision • Nov 19
Analysts lower revenue estimates to US$375.0k The 2020 consensus revenue estimate decreased from US$538.0k. Earnings per share (EPS) also decreased, with analysts lowering their estimates from -US$2.95 to -US$3.08 for the same period. The Biotechs industry in the US is expected to see an average net income growth of 6.5% next year. The consensus price target of US$14.25 was unchanged from the last update. Share price is down by 2.7% to US$3.57 over the past week. Analyst Estimate Surprise Post Earnings • Nov 14
Earnings beat expectations, revenue disappoints Revenue missed analyst estimates by 100%. Earnings per share (EPS) exceeded analyst estimates by 21%. Over the next year, revenue is expected to shrink by 73% compared to a 397% growth forecast for the Biotechs industry in the US. Is New 90 Day High Low • Oct 24
New 90-day low: US$3.10 The company is down 34% from its price of US$4.68 on 24 July 2020. The American market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. 